<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388215</url>
  </required_header>
  <id_info>
    <org_study_id>A86_03HT/DL1905</org_study_id>
    <nct_id>NCT04388215</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-828, D326, and D337 Combination Therapy in Hypertensive Patients With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to evaluate the efficacy and safety of CKD-828, D326, and D337 combination therapy in
      Hypertensive patients with Dyslipidemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this phase III study was to evaluate the efficacy and safety of
      CKD-348(CKD-828, D326, D337) tablet administration for treatment period(8 weeks) in essential
      hypertesive patients with Dyslipidemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change rate from baseline in Low Density Lipoprotein-C</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>(compare treatment group with comparator group 1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Mean Sitting Systolic Blood Pressure</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>(compare treatment group with comparator group 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change rate from baseline in Low Density Lipoprotein-C</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Low Density Lipoprotein-C</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and change rate from baseline in Total Cholesterol, Triglyceride, High Density Lipoprotein-C</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein-C target achievement rate accroding to National Cholesterol Education Program(NCEP) Third Adult Treatment Panel(ATP III) guideline at 4 weeks and 8 weeks</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Mean Sitting Systolic Blood Pressure</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Mean Sitting Diastolic Blood Pressure</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization rate of blood pressure after 4 weeks and 8 weeks</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>Blood Pressure &lt; 140/90 mmHg</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change and change rate from baseline in Low Density Lipoprotein-C, Total Cholesterol, Triglyceride, High Density Lipoprotein-C</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Low Density Lipoprotein-C target achievement rate accroding to National Cholesterol Education Program(NCEP) Third Adult Treatment Panel(ATP III) guideline at 4 weeks and 8 weeks</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in Mean Sitting Systolic Blood Pressure and Mean Mean Sitting Diastolic Blood Pressure</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Normalization rate of blood pressure after 4 weeks and 8 weeks</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>Blood Pressure &lt; 140/90 mmHg</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypertension</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: CKD-828 80/5mg, D326 20mg, D337 10mg, D013(placebo) 80mg
- CKD-828 80/5mg, D326 20mg, D337 10mg, D013(placebo) 80mg, orally, 1 tablet once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: CKD-828 80/5mg, D326(placebo) 20mg, D337(placebo) 10mg, D013(placebo) 80mg
- CKD-828 80/5mg, D326(placebo) 20mg, D337(placebo) 10mg, D337(placebo) 10mg, D013(placebo) 80mg, orally, 1 tablet once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: CKD-828(placebo) 80/5mg, D326 20mg, D337 10mg, D013 80mg
- CKD-828(placebo) 80/5mg, D326 20mg, D337 10mg, D013 80mg, orally, 1 tablet once a day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-828</intervention_name>
    <description>orally, 1 tablet once a day for 8 weeks</description>
    <arm_group_label>Comparator group 1</arm_group_label>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-828(placebo)</intervention_name>
    <description>orally, 1 tablet once a day for 8 weeks</description>
    <arm_group_label>Comparator group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D326</intervention_name>
    <description>orally, 1 tablet once a day for 8 weeks</description>
    <arm_group_label>Comparator group 2</arm_group_label>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D326(placebo)</intervention_name>
    <description>orally, 1 tablet once a day for 8 weeks</description>
    <arm_group_label>Comparator group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D337</intervention_name>
    <description>orally, 1 tablet once a day for 8 weeks</description>
    <arm_group_label>Comparator group 2</arm_group_label>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D337(placebo)</intervention_name>
    <description>orally, 1 tablet once a day for 8 weeks</description>
    <arm_group_label>Comparator group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D013</intervention_name>
    <description>orally, 1 tablet once a day for 8 weeks</description>
    <arm_group_label>Comparator group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D013(placebo)</intervention_name>
    <description>orally, 1 tablet once a day for 8 weeks</description>
    <arm_group_label>Comparator group 1</arm_group_label>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 19 years and 75 years old(male or female)

          2. Diagnosed essential hypertensive patients with dyslipidemia or the patients who has
             been taking antihypertensive and antidyslipidemic drugs

          3. The patients who can stop taking antihypertensive and antidyslipidemic drugs accroding
             to Principle Investigator's opinion

          4. Agreement with written informed consent

        Exclusion Criteria:

          1. Patients whose blood pressure measured at screening is one of the following:

               -  Mean Sitting Systolic Blood Pressure ≥ 200 mmHg or Mean Sitting Diastolic Blood
                  Pressure ≥ 120 mmHg

               -  Difference in Mean Sitting Systolic Blood Pressure between patient's both arms ≥
                  20 mmHg and Mean Sitting Diastolic Blood Pressure ≥ 10 mmHg

          2. Patients whose lipid level measured at screening is one of the following:

               -  Low Density Lipoprotein-C &gt; 250 mg/dL or Triglyceride ≥ 500 mg/dL

          3. Patients diagnosed with secondary hypertension or suspected of secondary
             hypertension(coarctation of aorta, primary aldosteronism, etc).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ChangGyu Park, M.D, Ph.D</last_name>
    <phone>+82-2-2626-3019</phone>
    <email>parkch@kumc.or.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Gyu Park, M.D, Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

